J&J submits FDA application for myasthenia gravis drug nipocalimab08/30/2024 [ad_1] J&J submits FDA application for myasthenia gravis drug nipocalimab [ad_2] Source: Seekingalpha
FDA accepts SpringWorks' application for mirdametinib for NF1-PN08/29/2024 [ad_1] FDA accepts SpringWorks’ application for mirdametinib for NF1-PN [ad_2] Source: Seekingalpha
